DSGN · CIK 0001807120
What Design Therapeutics, Inc. told the SEC could break it.
Design Therapeutics' disclosures are those of a pre-revenue biotech with a fragile supply chain. It has never generated product revenue, posted net losses of $69.8 million in 2025 and $49.6 million in 2024, and expects it will be years — if ever — before it has an approved product, leaving it reliant on equity financing. Its manufacturing is thin: it expects each product candidate to be covered only by single-source suppliers (with just one supplier for an excipient of DT-216P2, and a 2023 vial-stopper problem that already caused a delay). Because its active ingredients and excipients are made abroad, including in China, current or future tariffs would raise its R&D costs and could disrupt supply and clinical timelines.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source suppliers for product candidates (incl. one excipient for DT-216P2)high
Design has limited manufacturing arrangements and expects each product candidate to be covered only by single-source suppliers; it has just one supplier for an excipient of DT-216P2, and a 2023 vial-stopper issue already caused a supply delay.
“We currently have limited manufacturing arrangements and expect that each of our product candidates will only be covered by single source suppliers for the foreseeable future.”
SEC filing →As of 2026
Other disclosures
- pre-revenue with recurring net losses; years from any approved productmedium
Design has never generated product revenue and posted net losses of $69.8M (2025) and $49.6M (2024), expecting it will be several years, if ever, before it has an approved product — so it depends on equity financing (a $300M shelf / $100M ATM).
“We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations, including a net loss of $69.8 million and $49.6 million for the years ended December 31, 2025 and 2024, respectively.”
SEC filing →As of 2026
Regulatory & policy
- tariffs on China-sourced APIs/excipients raising R&D costsmedium
Design's APIs and excipients are manufactured in multiple foreign countries including China; current or future tariffs would raise R&D expenses (including API costs), add supply-chain complexity and could disrupt supply and delay clinical timelines.
“Such materials for our product candidates are currently manufactured in multiple foreign countries, including China. Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch